Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track MGX with free AI briefings, catalyst countdowns, and dilution alerts.

MGX · Metagenomi Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$137.8M Cash on Hand
21.4mo Cash Runway
Follow MGX by email Get an email when MGX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about MGX, unsubscribe in one click. Privacy

📣 What MGX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

MGX holds $137.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $19.3M/quarter from operations, an estimated runway of 21.4 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 33 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MGX files for a raise →

👥 Who Owns MGX

Insiders 10.3% Institutions (53 holders) 18.2% Public and other holders 71.5%
HolderTypeShares% of sharesAs of
Brian C. Thomas
Director · +196,000 options
Insider 2,762,142 7.31% 2026-06-30
Jian Irish
President and Chief Executive Officer, D · +641,000 options
Insider 668,106 1.77% 2026-09-08
Pamela Wapnick
Chief Financial Officer · +228,000 options
Insider 206,580 0.55% 2026-09-08
Matthew Wein
Title: General Counsel, Compliance Offic · +90,725 options
Insider 126,133 0.33% 2026-09-08
Sarah B. Noonberg
Chief Medical Officer · +84,000 options
Insider 109,135 0.29% 2025-06-06
Laurence Reid
Director · +59,400 options
Insider 20,000 0.05% 2026-09-09

Share count 37,805,669 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full MGX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MGX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.